Brief: Ionis Receives U.S. FDA Breakthrough Therapy Designation For Olezarsen For Severe Hypertriglyceridemia
01/12/2025 12:57
Dec 1 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR OLEZARSEN FOR SEVERE HYPERTRIGLYCERIDEMIA (SHTG) IONIS PHARMACEUTICALS INC: ON TRACK TO SUBMIT SUPPLEMENTAL NEW DRUG APPLICATION BY END OF YEAR Source text: ID:nBw35PqqDa Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study